Compare Heron Therapeutics Inc (HRTX) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.15 (market cap $3.80B). The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is far larger — about 55.9× Heron Therapeutics Inc's market cap, and Vanguard Global ex-US Real Estate Index Fd ETF is more actively traded (277,049 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| HRTX | VNQI | |
|---|---|---|
Market Cap | $68.01M | $3.80B |
Volume | 1,891,941 | 277,049 |
Sector | Health | — |
52-Week High | $1.49 | $50.76 |
52-Week Low | $0.27 | $41.81 |
Typical Hold Time | 35 Days | 95 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $41.82, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages unanimously negative, though oscillators suggest potential stabilization. The ETF focuses on international real estate across 30+ countries, offering a higher dividend yield than domestic counterparts but has underperformed in recent total returns. Recent news highlights a significant 45.9% drop in short interest as of September 15, 2026 (Defense World), indicating reduced bearish speculation.
The outlook remains cautious due to weak technical momentum and global real estate sector headwinds. Investment appeal lies in diversification benefits and attractive yield, but risks include currency fluctuations and economic sensitivity. Analyst comparisons favor VNQI for cost efficiency versus peers, though performance lag warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
